ArticleVaccine insights2022
The quest for vaccine-induced immune correlates of protection against tuberculosis.
Article in Vaccine insights, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Antigen-specific Th1 cytokine markers and protection against tuberculosis: a systematic review and meta-analysis stratified by progression to active disease and sustained IGRA conversion.Frontiers in cellular and infection microbiology · 2026Pooled it
- Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01The lancet. HIV · 2025Trial
- BCG Revaccination for the Prevention ofThe New England journal of medicine · 2025Trial
- Co-regulation of innate and adaptive immune responses induced by ID93+GLA-SE vaccination in humans.Frontiers in immunology · 2024Trial
- Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials.The Lancet. Microbe · 2026Review
- BCG vaccination induces antibacterial effector functions among Vδ1/3 T cells that are associated with protection against tuberculosis.Cell reports. Medicine · 2026Article
- Evaluation of the performance of promising host transcriptional biosignatures in predicting TB progression during a 1-year prospective cohort study in Indian household contacts.Frontiers in tuberculosis · 2026Article
- B cells and iBALT in TB immunity & pathogenesis.Frontiers in immunology · 2026Review
- Mycobacterium tuberculosis biology, pathogenicity and interaction with the host.Nature reviews. Microbiology · 2025Review
- The Central Importance of Vaccines to Mitigate the Threat of Antibiotic-Resistant Bacterial Pathogens.Vaccines · 2025Review
- Granulysin Antimicrobial Activity Promotes Dormancy in Mycobacterium tuberculosis.European journal of immunology · 2025Article
- De-risking vaccine development: lessons, challenges, and prospects.NPJ vaccines · 2025Review
- Vaccines for Global Health: Progress and Challenges.The Journal of infectious diseases · 2025Article
- TnSeq identifies genetic requirements of Mycobacterium tuberculosis for survival under vaccine-induced immunity.NPJ vaccines · 2025Article
- Driving innovation from discovery to access: Meeting report of the 7Gates open research · 2025Article
- Humoral correlate of vaccine-mediated protection from tuberculosis identified in humans and non-human primates.bioRxiv : the preprint server for biology · 2024Article
- Immune correlates of protection as a game changer in tuberculosis vaccine development.NPJ vaccines · 2024Review
- TB-vaccines: Current status & challenges.The Indian journal of medical research · 2024Review
- OMIP-101: 27-color flow cytometry panel for immunophenotyping of major leukocyte populations in fixed whole blood.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2024Article
- A spotlight on the tuberculosis epidemic in South Africa.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 2 countries.
Funding
Abstract
Immunization strategies against tuberculosis (TB) that confer better protection than neonatal vaccination with the 101-year-old Bacille Calmette-Guerin (BCG) are urgently needed to control the epidemic, but clinical development is hampered by a lack of established immune correlates of protection (CoPs). Two phase 2b clinical trials offer the first opportunity to discover human CoPs against TB. Adolescent BCG re-vaccination showed partial protection against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.